Top Read Articles

Published in last 1 year |  In last 2 years |  In last 3 years |  All

Please wait a minute...


For Selected: Download Citations EndNote Reference Manager ProCite BibTeX RefWorks Toggle Thumbnails

Select

Prognosis and risk factors of different recurrence patterns after hepatectomy for colorectal liver metastasis Chen Hanwei, Li Lei Electronic Journal of Liver Tumor    2024, 11 (2): 27-32.   Abstract （42）      PDF （3700KB）（16）       Knowledge map    Save Objective: To study the prognostic differences and risk factors of different recurrence patterns after hepatectomy for colorectal liver metastasis. Methods: The general data, clinical data and follow-up data of patients with colorectal liver metastasis who underwent hepatectomy in the Department of General Surgery of Peking University Third Hospital from January 2009 to February 2023 were collected. Kaplan-Meier curve was used to analyze the survival differences between different recurrence times and different recurrence sites. The maximally selected test was used to find the optimal cut-off value of recurrence time for distinguishing the survival after recurrence. Logistic regression analysis were used to analyze the risk factors of early recurrence. Results: A total of 281 patients met the inclusion and exclusion criteria. There were statistically significant differences in mortality and overall survival between patients with and without postoperative recurrence (P=0.001). The optimal cut-off value for distinguishing early and late recurrence was 12 months (P=0.001). There was a statistically significant difference in the post-recurrence survival between patients with early recurrence and late recurrence (P=0.001 1). There was a statistically significant difference in the post-recurrence survival between different recurrence sites (P=0.002 3), and the prognosis of patients with the first recurrence site in the lung was the best. Logistic regression analysis showed that patients with positive lymph node metastasis of primary tumor (OR=2.294, 95%CI:1.171-4.496, P=0.019), preoperative CEA≥5.31 ng/ml (OR=2.160, 95%CI:1.001-4.660, P=0.049 8) and preoperative CA19-9≥ 40.52 U/ml (OR=2.210, 95%CI:1.030-4.741, P=0.042) were at high risk of early recurrence after surgery. Conclusions: The recurrence within 12 months and extrapulmonary recurrence is associated with poor prognosis. The risk factors for early recurrence include positive lymph node metastasis of primary tumor, preoperative CEA≥5.31 ng/ml and preoperative CA19-9≥ 40.52 U/ml. Patients with related risk factors should be actively reviewed and monitored. Reference | Related Articles | Metrics

Select

Efficacy and safety of bevacizumab with nab-paclitaxel and tegafur gimeracil oteracil potassium capsule (S-1) in advanced biliary tract adenocarcinoma Zhang Chao, Sun Yongkun, Su Aijiang, Zhao Jianjun, Zhou Jianguo, Li Zhiyu, Zhou Hua, Zhao Pan, Chen Nan, Liu Na Electronic Journal of Liver Tumor    2024, 11 (2): 61-65.   Abstract （41）      PDF （2199KB）（19）       Knowledge map    Save Objective: To evaluate the efficacy and safety of bevacizumab with nab-paclitaxel and tegafur gimeracil oteracil potassium capsule (S-1) in advanced biliary tract adenocarcinoma patients. Method: Totally 22 stageⅣ biliary tract adenocarcinoma patients were enrolled in this single arm, single center prospective phaseⅡ study. Patients were treated with bevacizumab at a dose of 5 mg/kg on day 1, nab-paclitaxel at a dose of 150 mg/m2 on day 1 and S-1, 40 to 60 mg bid/day on days 1-10 of a 14-day cycle. Treatments were repeated until disease progression or unacceptable toxicity occurred. The primary endpoint was objective response rate (ORR). The secondary endpoints were median progression-free survival (PFS), disease control rate (DCR), and adverse events (AEs). Result: The number of patients enrolled were 22, and 21 patients were evaluated for efficacy, with a median of 6 cycles of treatment and a median of 2 lines of treatment. A total of 9 patients achieved partial response (PR) with an ORR of 42.9%(9/21), DCR was 85.7%(18/21). 3 progressive disease was observed. The median PFS were 8 months (95% confidence interval [95%CI]: 4.5~11.5). The incidence of grade 3 treatment-related adverse events in 22 patients was 68.2%(15/22), and there were no grade 4 treatment-related adverse events. The most common grade 3 or 4 toxicities were neutropenia (18.1%), Thrombocytopenia in 2 cases (9.1%), gastrointestinal reaction in 2 cases (9.1%), increased total bilirubin (TBIL)/direct bilirubin (DBIL) in 1 case (4.5%), anemia in 1 case (4.5%), others including neurotoxicity, elevated aminotransferase, bleeding, diarrhea, fatigue, elevation of blood pressure, proteinuria, etc., were grade 1 to 2. During treatment, 4 cases (18.1%) were combined with infection, 3 cases stopped treatment due to adverse events, and there were no treatment-related deaths. Conclusion: The combination of bevacizumab with nab-paclitaxel and S-1 showed explicit antitumor activities and favorable safety profile in advanced biliary tract adenocarcinoma patients, which has good clinical therapeutic value. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 1-13.   Abstract （40）      PDF （1944KB）（43）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Analysis of clinical features of multiple primary tumors associated with liver cancer Wu Wenqi, Wang Hao, Wang Yuxia Electronic Journal of Liver Tumor    2024, 11 (2): 33-36.   Abstract （39）      PDF （1988KB）（11）       Knowledge map    Save Objective: To explore the clinical epidemiological characteristics and survival outcomes of patients with multiple primary malignant tumors (MPMTs) combined with liver cancer. Methods: From August 2010 to June 2023, patients with liver cancer were selected from malignant tumor patients admitted to the Cancer Center of Peking University Third Hospital. The basic information of the patients and the incidence information of liver cancer and other tumors were collected to make comparisons between MPMTs and single liver cancer, also groups with liver cancer as the first or the second primary cancer. Results: The incidence of liver cancer combined with extraneous tumors was accounting for 13.1% (23/176) of liver cancer patients during the same period. Among the patients, 5 had synchronous multiple primary tumors, and 18 had metachronous multiple primary tumors. Of these patients, 9 had liver cancer as the first primary tumor, and 9 had liver cancer as the second primary tumor. Liver cancer patients with family history of cancer were more likely to have multiple primary tumors (χ2=5.22, P=0.030). Liver cancer as the first primary tumor had a shorter interval for multiple primary tumor onset compared to liver cancer as the second primary tumor (35 month vs. 156 month, P=0.009). The onset interval was negatively correlated with the diagnosis age of the first primary tumor (r=-0.60, P=0.009). Conclusions: Multiple primary tumors associated with liver cancer tend to occur in patients with a family history of cancer. There was a difference in the tumor incidence interval between multiple primary cancers with liver cancer as the first primary tumor and multiple primary cancers with liver cancer as the second primary tumor. Reference | Related Articles | Metrics

Select

Global liver and gallbladder cancer incidence and mortality in 2022 and projections to 2050 Liu Manqi, Xu Mengyuan, Shan Tianhao, Zhao Hong, Zeng Hongmei, Cai Jianqiang Electronic Journal of Liver Tumor    2024, 11 (2): 53-60.   Abstract （35）      PDF （2821KB）（14）       Knowledge map    Save Objective: To analyze the global epidemiological profiles of liver and gallbladder cancer in 2022, and project the global burden of cancer incidence and mortality until 2050. Methods: Based on the GLOBOCAN 2022 database, we analyzed the global burden of liver and gallbladder cancer in 2022 and the projected disease burden in 2050. We calculated age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) by using Segi's world standard population structure data. We estimated the future number of cases and deaths by 2050 based on world population prospects. Results: In 2022, there were an estimated 866,136 new cases and 758,725 deaths from liver cancer, corresponding to ASIRs and ASMRs of 8.6 per 100,000 and 7.4 per 100,000, respectively. There were an estimated 122,491 new cases and 89,055 deaths from gallbladder cancer, corresponding to ASIRs and ASMRs of 1.2 per 100,000 and 0.83 per 100,000, respectively. Incidence and mortality rates of liver cancer were higher in males than in females across different age groups, and gallbladder cancer displayed higher rates among females compared to males. The country with the highest ASIR and ASMR for liver cancer was Mongolia. For gallbladder cancer, Bolivia reported the highest ASIR and ASMR. By 2050, the annual number of new cases and deaths from liver cancer will increase to 1,564,034 (an 80.6 percent increase from the year 2022) and 1,420,926 (an 87.3 percent increase), respectively. The annual number of new cases and deaths from gallbladder cancer will increase to 235,096 (a 91.9 percent increase from the year 2022) and 176,725 (a 98.4 percent increase), respectively. Africa has the largest increase in both projected new cases and deaths from liver and gallbladder cancer globally in 2050. Conclusions: Inequities in liver and gallbladder disease burden persist worldwide. Regions such as Asia and Africa, as well as countries such as Mongolia and Bolivia, which face heavy disease burden and rising incidence rates, must prioritize the establishment of cancer control initiatives. Reference | Related Articles | Metrics

Select

Study on the development trend of liver cancer mortality among Chinese residents from 2012 to 2021 Shao Tang, Zheng Fangshu, Wu Jun Electronic Journal of Liver Tumor    2024, 11 (3): 54-57.   Abstract （29）      PDF （1992KB）（9）       Knowledge map    Save Objective: To analyze the trends of liver cancer mortality and standardized mortality among Chinese residents from 2012 to 2021. Methods: The trend of liver cancer mortality and standardized mortality among Chinese residents was studied and analyzed by using the Joinpoint regression model with the number of liver cancer deaths and survey population in the National Disease Surveillance System Cause of Death Surveillance Dataset (2012), the Chinese Cause of Death Surveillance Dataset (2013-2021), and the data from the 6th and 7th national census as the study data. Results: The number of liver cancer deaths and mortality rates among men in the surveillance population from 2012 to 2021 years were approximately 2.7 to 2.8 times higher than those among women. There were 2 Joinpoint turning points for liver cancer mortality in the total, male and female populations in the surveillance population from 2012 to 2021 years, with the turning points in the male population occurring in 2014 years and 2018 years, with an increasing trend from 2012 to 2014 years (P<0.05) and a decreasing trend from 2014 to 2018 years (P<0.05). The turning points in the total and female populations occurred in 2014 years and 2019 years, with an upward trend from 2012 to 2014 years (P<0.05) and a downward trend from 2014 to 2019 years (P<0.05). There was one Joinpoint turning point of liver cancer mortality in the total population, male population and female population, which occurred in 2019 years, and the female population showed an increasing trend from 2019 to 2021 years (P<0.05). Conclusion: The mortality rate of liver cancer in the monitored population was higher in males than in females, and its development trend showed an increasing trend before 2014 and a decreasing trend after 2014, and the trend of the standardized mortality rate of liver cancer tended to be stable. Reference | Related Articles | Metrics

Select

Effect of hepatic R1 margin on intrahepatic recurrence of colorectal cancer liver metastases Ai Xiangnan, Wang Hangyan, Zhang Wenxuan, Jin Changguo, Wu Zhenyu, Xiu Dianrong Electronic Journal of Liver Tumor    2024, 11 (2): 37-42.   Abstract （26）      PDF （2323KB）（5）       Knowledge map    Save Objective: The effect of R1 margin on liver resection for colorectal cancer liver metastasis (CRLM) has been controversial, and there is a lack of models for the effect of hepatic R1 margin on intrahepatic margin recurrence. This study aimed to construct a predictive model for intrahepatic margin recurrence in CRLM patients to understand whether there is an effect of R1 margin on intrahepatic margin recurrence. Methods: The data of 123 CRLM patients undergoing surgical treatment in the General Surgery Department of Peking University Third Hospital from January 2009 to December 2020 were retrospectively analyzed, and the factors with independent predictive value for intrahepatic margin recurrence were established through binary Logistic regression analysis, and the predictive model was established. Results: The whole cohort had 48 (39.0%) and 75 (61.0%) non-hepatic recurrence.73 (59.3%) of R0 resection and 50 (40.7%) of R1 resection. In the univariate regression analysis, the maximum diameter of metastases (OR=2.396, P=0.041), non-anatomical resection (OR=3.732, P=0.025), operation duration (OR=2.571, P=0.013), liver R1 margin (OR=2.907, P=0.005) were significantly associated with hepatic R. margin recurrence. After multivariate regression analysis, R1 margin was no longer statistically significant (OR=2.103, 95%CI: 0.94-4.65, P=4.70), while metastasis with maximum diameter >21 mm (OR=2.509, 95%CI: 1.02-6.17, P=0.045) and non-anatomical resection (OR=3.585, 95%CI: 1.06-12.15, P=0.040) had independent predictive value for intrahepatic margin recurrence. Conclusions: The R1 margin in the model established in this study seemed to increase the risk of intrahepatic margin recurrence, but did not reach statistical significance. Independent risk factors affecting intrahepatic margin recurrence were the maximum diameter of hepatic metastases and non-anatomical resection. Reference | Related Articles | Metrics

Select

Clinical and pathological factors affecting the prognosis of patients with colorectal liver metastasis Wang Peng, Du Jundong, Wang Hangyan, Xiu Dianrong Electronic Journal of Liver Tumor    2024, 11 (2): 43-47.   Abstract （26）      PDF （2377KB）（6）       Knowledge map    Save Objective: To investigate the clinical and pathological factors affecting the prognosis of patients with colorectal liver metastases (CRLM) patients. Method: Patients with synchronous CRLM who were admitted to Peking University Third Hospital from March 2014 to March 2016 were retrospectively analyzed. The relevant clinical data, pathology of primary tumor and liver metastases of each patient were collected, and the patients were followed up. Univariate analysis and Cox regression were used to analyze the independent prognostic factors of CRLM. Result: A total of 97 patients with CRLM were included in this study, including 57 males and 40 females, with an average age of (61.2±11.8) years, 54 cases in the right colon and 43 cases in the left colon and rectum. Univariate analysis showed that preoperative carcinoembryonic antigen (CEA)>32 ng/ml, preoperative carbohydrate antigen19-9 (CA19-9)>20 U/ml, presence of cancer nodules, postoperative N stage, primary tumor located in the right hemicolon, the number of liver metastases>3, and poor differentiation of the primary tumor were non-independent risk factors affecting the 3-year overall survival of patients (all P<0.05). Cox regression model was used for multivariate analysis, the results showed that preoperative CEA level (hazard ratio [HR]=2.123, 95% confidence interval [95%CI]: 1.151-3.918), preoperative CA19-9 level (HR=2.022, 95%CI: 1.094-3.738), primary tumor location (HR=0.502, 95%CI: 0.265-0.951) and tumor differentiation (HR=0.519, 95%CI: 0.300-0.899) were independent risk factors for prognosis. Conclusion: The primary tumor located in the right hemicolon, the primary tumor poorly differentiated, the preoperative CEA >32 ng/ml, and the preoperative CA19-9 >20 U/ml are independent risk factors affecting the prognosis of patients with CRLM. Reference | Related Articles | Metrics

Select

The overexpression of miRNA-10a promotes liver regeneration in rats with liver cirrhosis after hepatectomy Yu Zhencen, Gu Xiaohui, Liu Chao, Wang Xin Electronic Journal of Liver Tumor    2024, 11 (2): 48-52.   Abstract （26）      PDF （3705KB）（8）       Knowledge map    Save Objective: To investigate the effect of miRNA-10a on liver regeneration in rats after liver resection in liver cirrhosis. Methods: Thirty-six cirrhotic rats were randomly divided into a sham operation group (Group A, n=12), a 70% liver resection without transfection group (Group B, n=12), and a 70% liver resection with transfection group (Group C, n=12). Two weeks before surgery, successful hepatocyte-specific transfection of miRNA-10a was performed in rats of Group C. At 12h, 24h, 48h, and 72h after surgery, 3 rats from each group were euthanized, and blood samples from the portal vein were collected for testing serum liver function indicators including alanine aminotransferase (ALT) and albumin (ALB). The levels of miRNA-10a in liver tissue were detected using PCR, and the liver-to-body weight ratio was calculated at different time points. Results: At 12 h, 24 h, 48 h, and 72 h after surgery, the levels of miRNA-10a in liver tissue of Group C rats were significantly higher than the other two groups, indicating successful overexpression of miRNA-10a. At 12 h, 24 h, 48 h, and 72 h after surgery, the serum ALT levels of Group C rats were lower on average than Group B, while the ALB levels were higher on average than Group B, suggesting that miRNA-10a is beneficial for protecting liver function. At 48 h and 72 h after surgery, the liver-to-body weight ratio of Group C rats was significantly higher than Group B, indicating that overexpression of miRNA-10a promotes liver tissue growth. Conclusion: Overexpression of miRNA-10a promotes liver regeneration in rats with liver cirrhosis after hepatectomy. Reference | Related Articles | Metrics

Select

Study on the development track of early fatigue after liver transplantation Xi Shuangmei, Zhang Lili, Gu Yanmei, Guo Huimin, Liu Xin, Zheng Yulin, Jin Boxun, Li Guangming Electronic Journal of Liver Tumor    2024, 11 (2): 94-99.   Abstract （26）      PDF （2176KB）（9）       Knowledge map    Save Objective: To explore the development track of early fatigue after liver transplantation and its influencing factors. Methods: 96 liver transplant patients who were followed up in the liver transplant center of our hospital from January 2019 to March 2023 were selected as the research objects. Fatigue assessment scale (FAI) was used to evaluate the fatigue of patients at 1 week, 2 weeks, 1 month, 3 months and 6 months after liver transplantation, and growth mixed model (LGMM) was used to analyze and identify the early fatigue development track of patients after liver transplantation. The general data, social support and psychological state of patients were collected, and the influencing factors of patients' early fatigue development track were analyzed by multi-classification Logistic regression. Results: During the 6-month follow-up, there were 91 patients with complete follow-up data of FAI scale, and finally 91 patients were included. LGMM analysis showed that the early fatigue development trend of patients after liver transplantation was divided into three types, namely, descending group(n=36), stable group(n=34) and ascending group(n=21). The fatigue development of all three groups had a time effect. The FAI score of descending group decreased significantly with time, while that of stable group did not change significantly with time, while that of ascending group increased significantly with time. Logistic regression analysis showed that age, anxiety, depression, sleep status and social support level were the influencing factors of early fatigue development after liver transplantation (P<0.05). Conclusion: The development track of early fatigue in patients after liver transplantation is heterogeneous, and there are different types of development trends, among which age, anxiety, depression, sleep state and social support level are the influencing factors. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (2): 1-26.   Abstract （25）      PDF （4919KB）（6）       Knowledge map    Save Related Articles | Metrics

Select

A new strategy for solid tumor treatment: the immunotherapeutic potential of chimeric antigen receptor macrophages Kong Qinghao, Li Shuang, Lu Yinying Electronic Journal of Liver Tumor    2024, 11 (3): 16-19.   Abstract （24）      PDF （1898KB）（6）       Knowledge map    Save Solid tumors are one of the major diseases threatening human health worldwide. Traditional treatments such as surgery, radiotherapy, and chemotherapy have their inherent limitations, and although immune checkpoint inhibitors have shown efficacy, not all patients respond to them. Chimeric antigen receptor-macrophage (CAR-M) therapy involves the genetic engineering of macrophages to express chimeric receptors that specifically recognize tumor antigens, demonstrating the potential for targeted tumor cell destruction. However, CAR-M therapy for solid tumors is currently in the preclinical and early clinical research stages. This paper provides a comprehensive review of the current state of preclinical studies on CAR-M, including the design of CAR structures, sources of donor cells, and vectors for delivering CAR genes to macrophages. Additionally, it summarizes the limitations and challenges faced in the development of CAR-M, offering new research perspectives for the future advancement of CAR-M therapy. Reference | Related Articles | Metrics

Select

From susceptibility to prognosis: the multifaceted role of the cytochrome p450 family in hepatocellular carcinoma Hong Shengjie, Zhang Guangquan, Li Ruixi, He Yongfei, Wu Fenfang, Shi Xianjie Electronic Journal of Liver Tumor    2024, 11 (3): 58-63.   Abstract （24）      PDF （2799KB）（5）       Knowledge map    Save The cytochrome P450 (CYP450) family is a group of enzymes that play a crucial role in the metabolism of exogenous and endogenous compounds. Growing evidence suggests that the CYP450 family is pivotal in the occurrence, progression, and prognosis of hepatocellular carcinoma (HCC). Polymorphisms in CYP450 family genes can influence an individual's susceptibility to carcinogens and metabolic capacity, closely associated with the risk of HCC. Furthermore, dysregulation of CYP450 family genes is involved in HCC progression, with mechanisms encompassing reactive oxygen species levels, DNA damage, cell proliferation, invasion, and apoptosis. The expression levels of CYP450 family genes are also intimately linked to the prognosis of HCC patients, showing promise as essential indicators for prognostic assessment. In conclusion, a deep understanding of the role of the CYP450 family in the occurrence, progression, and prognosis of HCC is of great significance for elucidating the molecular mechanisms of HCC and developing individualized prevention and treatment strategies. Future research should further investigate the molecular mechanisms underlying the polymorphisms and dysregulation of CYP450 family genes, establish corresponding risk prediction and prognostic evaluation models, and emphasize the regulatory effects of drugs on the CYP450 family, aiming to provide new strategies and targets for the prevention and treatment of HCC. Reference | Related Articles | Metrics

Select

Preliminary observe of the efficacy and safety of mixed liver cancer immunotherapy Liang Jun, Yang Zhenyun, Zhang Yaojun, Chen Minshan, Hu Dandan Electronic Journal of Liver Tumor    2024, 11 (3): 20-24.   Abstract （22）      PDF （2247KB）（6）       Knowledge map    Save Objective: To observe preliminary the efficacy and safety of immune checkpoint inhibitors in the treatment of mixed liver cancer. Methods: From January 2018 to December 2023, clinical data of patients admitted to the Cancer Prevention Center of Sun Yat-sen University were collected, including basic information, treatment plan, laboratory indicators and survival status. Efficacy was assessed by response evaluation criteria in solid tumors v1.1 for solid tumors. The survival analysis with Kaplan-Meier curve. The univariate and multivariate analysis with Cox regression model. Results: A total of 21 patients with mixed liver cancer were collected. The median age was 55 years. The objective response rate was 28.6%. The disease control rate was 52.4%. The median progression-free survival time was 12.4 months (95%CI : 6.7-18.1 months). The median overall survival time was 14.4 months (95%CI: 10.4-18.4 months). Multivariate analysis showed that cancer thrombus (HR=3.95, 95%CI: 1.09-14.28, P=0.036) and increased carcinoembryonic antigen levels (>5 μg/L) (HR=5.46, 95%CI: 1.14-26.17, P=0.034) were associated with poor progression-free survival time. Adverse events of any level were controllable and no adverse event-related deaths. Conclusion: Preliminary observe shows that the immune checkpoint inhibitors have good efficacy and safety in the treatment of mixed liver cancer, and the increased thrombus and increased antigen level (> 5 μg/L) may be adverse factors to shorten the progression-free survival time. Reference | Related Articles | Metrics

Select

The prognostic value of preoperative platelet to neutrophil ratio in colorectal cancer patients with resectable synchronous liver metastases Zhang Jixin, Wu Liang, Wu Xueliang, Wang Likun, Ma Hongqing, Han Lei Electronic Journal of Liver Tumor    2024, 11 (2): 66-71.   Abstract （22）      PDF （2538KB）（10）       Knowledge map    Save Objective: To investigate the prognostic value of preoperative serum platelet to lymphocyte ratios (PLR) in colorectal cancer patients with synchronous liver metastases. Methods: The 74 patients clinicopathological data of in colorectal cancer patients with synchronous liver metastases who underwent liver resection in First Affiliated Hospital of Hebei North University were collected retrospectively. The X-tile software was used to calculate the best cut-off value of PLR toward prognosis, and the patients were divided into low PLR group (n=31) and high PLR group (n=43) according to the aforementioned cut-off value. Differences in general clinicopathological data and prognosis of the two group patients were investigated. Results: The best cut-off for PLR prognosis was 188, PLR≥188 was the high PLR group and PLR<188 was the low PLR group. Compared with patients in the low PLR group, the tumor stage of the high PLR group was later, the lymph node metastasis rate was higher, and the number of liver metastases was more (all P<0.05). The median survival time of patients in the high PLR group and the low PLR group were 33 months and 11 months (P=0.001), respectively. The Cox model multivariate analysis showed that pT staging (HR=2.199, 95%CI: 1.156-4.182, P=0.016), carcinoembryonic antigen ≥3.4 ng/ml (HR=1.834, 95%CI: 1.079-3.117, P=0.025), and PLR≥188 (HR=1.885, 95%CI: 1.022-3.477, P=0.042) were independent risk factors for the colorectal cancer patients with synchronous liver metastases. The prognostic prediction model was constructed according to the results of the survival analysis, and the validity curve and the receiver operation characteristic curve showed good model fit and accuracy. Conclusions: Preoperative PLR is closely related to the poor prognosis of colorectal cancer patients with synchronous liver metastases. Patients with preoperative PLR≥188 have a worse prognosis. The survival prediction models is constructed based on PLR, T stage and carcinoembryonic antigen have high accuracy and can be used to guide clinical practice. Reference | Related Articles | Metrics

Select

Expression and clinical significance of transmembrane protein 132A in liver cancer based on bioinformatics Zhao Hangqi, Ma Xiaowen, Zhang Tian'ai, Li Baifeng Electronic Journal of Liver Tumor    2024, 11 (3): 33-41.   Abstract （21）      PDF （9212KB）（12）       Knowledge map    Save Objective: To explore the expression pattern and clinical significance of transmembrane protein 132A (TMEM132A) in liver cancer based on public databases. Methods: The Cancer Genome Atlas and GSE14520, GSE60502 of Gene Expression Omnibus was used to analyze the mRNA level of TMEM132A in liver cancer and adjacent tissues, the promoter methylation level, and the correlation with clinical factors. The immunohistochemical results of TMEM132A in tissues were obtained through HPA database. Kaplan-Meier method was used to explore the correlation between TMEM132A and the prognosis of patients. Receiver operating characteristic curve was used to explore whether TMEM132A could accurately diagnose patients. The drug sensitivity of TMEM132A to chemotherapy drugs was predicted by cancer drug sensitivity genomics. Immune analysis of TEME132A was performed by single-sample GSEA, TIMER, STORMAL SCORE and immune checkpoint heatmap. Linkedomics website was used to perform gene set enrichment analysis for differential genes of TMEM132A. The STRING database was used to predict the interacting proteins of TMEM132A. Results: The expression of MEM132A in HCC tissues was significantly higher than that in adjacent tissues (P<0.05), and it was located in the cytoplasm and cell membrane. The high expression of TMEM132A was positively correlated with tumor stage, grade, AFP level and body weight. High expression of TMEM132A indicates poor prognosis and can be used as an accurate diagnostic indicator. TMEM132A is sensitive to a variety of chemotherapy drugs and infiltrated by a variety of immune cells, which can be used as a research target for drug therapy and immunotherapy. The promoter methylation level of TMEM132 was significantly decreased in cancer tissues. TMEM132A affects cell adhesion, fatty acid metabolism and other signaling pathways. Conclusion: TMEM132A is highly expressed in HCC and positively correlated with poor prognosis. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (2): 100-103.   Abstract （21）      PDF （5205KB）（20）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (2): 104-108.   Abstract （20）      PDF （1835KB）（8）       Knowledge map    Save Related Articles | Metrics

Select

Clinical features and prognosis analysis of combined mixed hepatocellular carcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma after surgical resection: propensity match analysis Zhu Runze, Mu Shaowei, Li Zhao, Zhu Jiye, Gao Jie Electronic Journal of Liver Tumor    2024, 11 (3): 25-32.   Abstract （20）      PDF （2576KB）（12）       Knowledge map    Save Objective: To compare the clinicopathological features and prognosis of mixed hepatocellular carcinoma (mHCC), hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) after surgical resection. Methods: The clinical data of 317 patients diagnosed with liver malignant tumors who were admitted to the Department of Hepatobiliary Surgery, Peking University People's Hospital from January 2015 to December 2023 were retrospectively analyzed. After propensity matching with 1:1 in the degree of tumor differentiation, lymph node metastasis and AJCC (8th edition) stage, 150 patients were enrolled in two independent matching cohorts: mHCC and HCC 43 cases each, mHCC and ICC 32 cases each. The clinical characteristics and prognosis of patients were compared between groups. Normally distributed continuous variables were compared using Student's t-test or one-way ANOVA, and non-normally distributed continuous variables were compared using Wilcoxon rank sum statistics. Chi-square test is used to compare categorical variables. The Kaplan-Meier method assesses median survival and median disease-free survival. Results: The age, sex, and degree of cirrhosis of mHCC patients were similar to those of HCC and ICC patients, and the prevalence of hepatitis B was lower than that of HCC patients but comparable to that of ICC patients. mHCC patients had significantly higher levels of AFP than those of ICC patients, lower levels of CA19-9 than those of HCC patients, and significantly higher levels of CEA than those of the other two pathological types. mHCC's pathological features of microvascular invasion rate and lymph node metastasis rate were higher than those of HCC and comparable to those of ICC.The median survival of mHCC patients was worse than that of HCC patients (19.6 months vs. 70.8 months, P<0.001) and comparable to that of ICC patients (19.6 months vs. 40.6 months, P=0.07). mHCC patients had a worse disease-free survival than that of HCC patients and comparable to that of ICC patients. Multifactorial Cox analysis showed that lymph node metastasis, poorly differentiated tumor, tumor stage, pathological type and history of alcohol consumption were independent risk factors associated with prognosis, and that poorly differentiated tumor and tumor stage were independent risk factors for disease-free survival; multiple tumors were an independent risk factor affecting postoperative prognosis in both 1:1 matched cohorts. Conclusions: The clinical features and prognosis of mHCC are not consistent with those of HCC and ICC, and it is a rare pathological type with a high degree of malignancy that is highly susceptible to recurrence, and it should be treated as a unique tumor type in primary hepatocellular carcinoma. The mHCC has a poorer long-term survival than HCC, and it is comparable to that of ICC, and lymph node metastasis, poorly differentiated tumors, tumor stage, and a history of alcohol consumption are prognostically relevant independent risk factors, luminal surgery was a prognostically relevant independent insurance factor, and poorly differentiated tumors and tumor stage were independent risk factors for disease-free survival. The multiple tumors were found to be associated with poor prognosis and recurrent metastases in mHCC after propensity matching. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 64-67.   Abstract （17）      PDF （3734KB）（5）       Knowledge map    Save Reference | Related Articles | Metrics